Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631720 · ClinicalTrials.gov registry record
CLAD Phenotype Specific Risk Factors and Mechanisms
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 884
- Enrollment target
NCT02631720 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 884 participants.
The verdict
NCT02631720 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 884 participants
- Enrollment target
Study Summary
While many patients experience benefits from transplant, complications such as infections and lung rejection may affect long term survival and quality of life. In this study doctors are looking at a complication called Chronic Lung Allograft Dysfunction (CLAD). CLAD is thought to be chronic rejection of the lung by the immune system and is the leading cause of death after lung transplantation. The purpose of this study is to help doctors determine: * why some people get CLAD and others do not * how patients who get CLAD do after CLAD is diagnosed * how CLAD may affect quality of life
Interventions
- PROCEDURE Bronchoscopy
- PROCEDURE Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 884 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2019-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02631720
The ClinicalTrials.gov registry entry for NCT02631720 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 884 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bronchoscopy is the first listed.
NCT02631720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02631720 about?
NCT02631720 is a clinical study titled "CLAD Phenotype Specific Risk Factors and Mechanisms". While many patients experience benefits from transplant, complications such as infections and lung rejection may affect long term survival and quality of life. In this study doctors are looking at a complication called Chronic Lung Allograft Dysfunction (CLAD). CLAD is thought to be chronic rejectio...
What is the current status of trial NCT02631720?
This trial is currently completed. The enrollment target is 884 participants. The study started on 2015-12-22. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT02631720?
The interventions under investigation include: Bronchoscopy (PROCEDURE), Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT02631720?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.